Literature DB >> 6822421

Localization of complement component 3 on Streptococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule.

E J Brown, K A Joiner, R M Cole, M Berger.   

Abstract

We have previously shown that complement component 3 (C3) deposited onto encapsulated Streptococcus pneumoniae by anti-capsular antibody (Ab) is a more efficient opsonin in vitro and in vivo than C3 deposited by anti-cell wall Ab (Brown et al., J. Clin. Invest. 69:85-98, 1982). In the present study, we explored the cellular location of C3b molecules that differ in opsonic efficiency by using avidin-ferritin to localize biotinylated Ab and C3 molecules on S. pneumoniae for electron microscopy. Anti-cell wall Ab and C3b molecules deposited by this Ab on unencapsulated S. pneumoniae were localized to S. pneumoniae cell walls. Anti-capsular Ab and C3b deposited by this Ab were seen in clusters on encapsulated S. pneumoniae at a distance from the cell wall. However, no avidin-ferritin staining of encapsulated S. pneumoniae was seen on incubation with biotinyl-anti-cell wall Ab, biotinylated C3 fixed by anti-cell wall Ab, or nonimmune serum containing biotinyl-C3. In each case, uptake of the biotinylated component was proven by radioactivity measurements, since biotinylated Ab and C3 were also radiolabeled with 125I. When avidin-ferritin did not bind to biotinylated components. Ouchterlony analysis indicated that C3 was bound to cell wall components on the encapsulated organisms. Thus, we conclude that, for encapsulated S. pneumoniae, opsonically efficient C3b molecules, deposited by anti-capsular Ab, are located on the S. pneumoniae capsule, whereas the opsonically inefficient C3b molecules deposited by anti-cell wall Ab or nonimmune serum are located on the cell wall. A major reason for the increased virulence of encapsulated compared to unencapsulated S. pneumoniae is that, in the absence of anti-capsular Ab, the S. pneumoniae capsule interferes with the recognition of cell wall-bound C3b molecules by phagocytic cell receptors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6822421      PMCID: PMC347953          DOI: 10.1128/iai.39.1.403-409.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  Activation of the alternative pathway by pneumococcal cell walls.

Authors:  J A Winkelstein; A Tomasz
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

2.  Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid.

Authors:  J A Winkelstein; A Tomasz
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

3.  The role of the capsular polysaccharide in the activation of the alternative pathway by the pneumococcus.

Authors:  J A Winkelstein; J A Bocchini; G Schiffman
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

4.  The avidin-biotin complex in affinity cytochemistry.

Authors:  E A Bayer; E Skutelsky; M Wilchek
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

5.  Heat labile opsonins to Pneumococcus. 3. The participation of immunoglobulin and of the alternate pathway of C3 activation.

Authors:  J A Winkelstein; H S Shin; W B Wood
Journal:  J Immunol       Date:  1972-06       Impact factor: 5.422

6.  The Forssman antigen of pneumococcus.

Authors:  M Fujiwara
Journal:  Jpn J Exp Med       Date:  1967-12

7.  Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine.

Authors:  S W Hosea; C G Burch; E J Brown; R A Berg; M M Frank
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

8.  The isolation of IgG from mammalian sera with the aid of caprylic acid.

Authors:  M Steinbuch; R Audran
Journal:  Arch Biochem Biophys       Date:  1969-11       Impact factor: 4.013

9.  A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia.

Authors:  E J Brown; S W Hosea; C H Hammer; C G Burch; M M Frank
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

10.  Large scale isolation of functionally active components of the human complement system.

Authors:  C H Hammer; G H Wirtz; L Renfer; H D Gresham; B F Tack
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

View more
  42 in total

1.  Pneumolysin-induced complement depletion during experimental pneumococcal bacteremia.

Authors:  R B Alcantara; L C Preheim; M J Gentry-Nielsen
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

2.  Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Authors:  Maija Toropainen; Leena Saarinen; Gestur Vidarsson; Helena Käyhty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.

Authors:  Melanie Abeyta; Gail G Hardy; Janet Yother
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

4.  Working mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 Protease.

Authors:  Gestur Vidarsson; Natasja Overbeeke; Annette M Stemerding; Germie van den Dobbelsteen; Peter van Ulsen; Peter van der Ley; Mogens Kilian; Jan G J van de Winkel
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.

Authors:  Marcellene A Gates; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

6.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

7.  The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of Salmonella enterica serotype Typhi.

Authors:  R Paul Wilson; Sebastian E Winter; Alanna M Spees; Maria G Winter; Jessalyn H Nishimori; Jesus F Sanchez; Sean-Paul Nuccio; Robert W Crawford; Çagla Tükel; Andreas J Bäumler
Journal:  Infect Immun       Date:  2010-11-22       Impact factor: 3.441

8.  Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies.

Authors:  W T Jansen; J Gootjes; M Zelle; D V Madore; J Verhoef; H Snippe; A F Verheul
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

9.  Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae.

Authors:  D S Chudwin; S G Artrip; A Korenblit; G Schiffman; S Rao
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

10.  Biochemical activities of Streptococcus pneumoniae serotype 2 capsular glycosyltransferases and significance of suppressor mutations affecting the initiating glycosyltransferase Cps2E.

Authors:  David B A James; Kanupriya Gupta; Jocelyn R Hauser; Janet Yother
Journal:  J Bacteriol       Date:  2013-10-04       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.